7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
• HIV: 2/3 pulmonary ... characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
RIPE Therapy - Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis - IDSA Guidelines

#Tuberculosis #ActiveTB #RIPE #Therapy
Microbiologically Confirmed Pulmonary ... Tuberculosis - ... #Tuberculosis ... #medications #pharmacology ... #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
• HIV: 2/3 pulmonary ... characteristic features Clinical ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... Multi-Drug Resistant Tuberculosis ... antimicrobials #regimens #pharmacology ... #dosing #idsa #
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... HIV-infected persons with clinical ... #TB #IDSA #Prevention ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
IDSA Recommendations ... Infection (Diffuse Pulmonary ... • Use until clinical ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... disease based on clinical ... Note: Active TB ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology